Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jeil Pharmaceutical Co., Ltd. (271980:KRX), powered by AI.
Jeil Pharmaceutical Co., Ltd. is currently trading at ₩10,700. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jeil Pharmaceutical Co., Ltd. on Alpha Lenz.
Jeil Pharmaceutical Co., Ltd.'s P/E ratio is 6.7.
“Jeil Pharmaceutical Co., Ltd. trades at a P/E of 6.7 (undervalued) with solid ROE of 11.7%.”
Ask for details →Jeil Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, and manufacturing of a wide array of medications. Established as a key figure within the healthcare sector, Jeil Pharmaceutical focuses on providing innovative and effective pharmaceuticals to enhance public health and quality of life. The company is involved in the production of both prescription and over-the-counter drugs, catering to diverse therapeutic areas such as cardiovascular, gastrointestinal, and metabolic disorders. Jeil Pharmaceutical is noted for its commitment to R&D, consistently investing in the development of new drugs and biosimilars, which helps in maintaining its competitive edge in a dynamic marketplace. The company operates within a robust regulatory framework, adhering to stringent quality standards to ensure the safety and efficacy of its products. In the financial market, Jeil Pharmaceutical Co., Ltd. plays a significant role as it contributes to the vitality of the healthcare ecosystem by addressing essential medical needs and offering healthcare solutions globally.
“Jeil Pharmaceutical Co., Ltd. trades at a P/E of 6.7 (undervalued) with solid ROE of 11.7%.”
Ask for details →Jeil Pharmaceutical Co., Ltd. (ticker: 271980) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 947 employees. Market cap is $157.3B.
The current price is ₩10,700 with a P/E ratio of 6.73x and P/B of 0.75x.
ROE is 11.71% and operating margin is 3.70%. Annual revenue is $567.2B.